Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Open-Label Study of Nedosiran (DCR-PHXC) in Primary Hyperoxaluria Type 1 or 2 With Severe Renal Impairment
2020-002826-97Phase 2Withdrawn
- Sponsor
- Dicerna Pharmaceuticals, Inc.
- Start
- Sep 2020
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nedosiran in Primary Hyperoxaluria Type 1 (PH1), Primary Hyperoxaluria Type 2 (PH2) and hyperoxaluria, sponsored by Dicerna Pharmaceuticals, Inc. Primary endpoint: Safety: TEAEs and SAEs, ECG, physical examination, vital signs, and clinical laboratory tests. Planned start Sep 2020; status: withdrawn.
02
Drugs
nedosiran
03
Conditions
Primary Hyperoxaluria Type 1 (PH1)Primary Hyperoxaluria Type 2 (PH2)hyperoxaluria
Beyond the preview
Go deeper on 2020-002826-97.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-002826-97.